The IL-1 system in HIV infection: Peripheral concentrations of IL-1β, IL-1 receptor antagonist and soluble IL-1 receptor type II

Clinical and Experimental Immunology

Volumn 109, Issue 1, 1997, Pages 54-58

  Kreuzer, K A ^b   Dayer, J M ^a   Rockstroh, J K ^b   Sauerbruch, T ^b   Spengler, U ^b  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

HIV infection; IL 1; IL 1 receptor antagonist; Soluble IL 1 receptors

Indexed keywords

BETA 2 MICROGLOBULIN; BINDING PROTEIN; CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; NEOPTERIN; TUMOR NECROSIS FACTOR RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SERUM; VIRUS INFECTION;

EID: 0030795924     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.4181315.x     Document Type: Article

References (37)

1. 2 release by rheumatoid synovial cells. J Clin Invest 1979; 64:1386-92.
2. Okusawa S, Gelfland JA, Ikejima T et al. Interleukin-1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81:1162-7.
3. Ohlsson K, Björk P, Bergenfeldt M et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348:550-2.
4. Dayer JM, Fenner H. The role of cytokines and cytokine inhibitors in arthritis. In: Emery P, ed. Baillière's clinical rheumatology, Vol. 6. London: Baillière Tindall, 1992:485-91.
5. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1992; 4:754-9.
6. Bendtzen K, Mandrup-Poulsen T, Nerup J et al. Cytotoxicity of human p7 interleukin-1 for pancreatic islets of Langerhans. Science 1986; 232:1545-7.
7. Louie S, Cai J Law R et al. Effects of interleukin-1 and interleukin-1 receptor antagonist in AIDS-Kaposi's sarcoma. J AIDS Hum Retrovir 1995; 8:455-60.
8. Weiss JM, Sundar SK. Interleukin-1: effects in the central nervous system and relevance to AIDS. Clinical Neuropharmacol 1992; 15:661A-2A.
9. Maury CPJ, Lahdevirta J. Correlation of serum cytokine levels with haematological abnormalities in human immunodeficiency virus infection. J Int Med 1990; 227:253-7.
10. Folks TM, Justement J, Kinter A et al. Cytokine-induced expression of HIV-1 in a chronically infected promonocvte cell line. Science 1987; 238:800-2.
11. Moore MAS, Warren DJ. Synergy of interleukin-1 and granulocyte colony-stimulating factor: in vivo stimulation of stem cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc Nat Acad Sci USA 1987; 84:7134-8.
12. Neta R, Douches S, Oppenheim JJ. Interleukin-1 is a radioprotector. J Immunol 1986; 136:2483-5.
13. Seckinger P, Lowenthal JW, Williamson K et al. A urine inhibitor of interleukin-1 activity that blocks ligand binding. J lmmunol 1987; 139:1546-9.
14. Seckinger P, Williamson K, Balavoine JF et al. A urine inhibitor of interleukin-1 activity affects both interleukin-1 alpha and 1 beta but not tumor necrosis factor-alpha. J Immunol 1987; 139:1541-5.
15. Galve de Rochemonteix B, Dayer J-M, Junod AF, Fibroblast-alveolar cell interactions in sarcoidosis and idiopathic pulmonary librosis: evidence for stimulatory and inhibitory cytokine production by alveolar cells. Eur Respir J 1990; 3:653-64.
16. Gabay C, Gay-Crosier F, Roux-Lombard P et al. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis: a biological marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994; 37:1744-51.
17. Zavala F, Rimaniol AC, Boussin F et al. HIV predominantly induces IL-1 receptor antagonist over IL-1 synthesis in human primary monocytes. J Immunol 1995; 155:2784-93.
18. Symons JA, Eastgate JA, Duff GW. Purification and characterization of a novel soluble receptor for interleukin-1. J Exp Med 1991; 174:1251-4.
19. Colotta F, Re F, Muzio M et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1994; 261:472-5.
20. Shattock RJ, Burger D, Dayer J-M et al. Enhanced HIV replication in monocytic cells following engagement of adhesion molecules and contact with stimulated T cells. Res Virol 1996; 147:171-9.
21. Barre-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-71.
22. Lai PK, Tamura Y, Bradley WG et al. Cytokine regulation of the human immunodeficiency virus (HIV). Int J Immunopharmacol 1991; 13:55-61.
23. + cells at various stages of human immunodeficiency virus I infection in children. Pediatr Infect Dis J 1991; 10:450-4.
24. Aukrust P, Liabakk N-B, Muller F et al. Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical, immunologic and virologic parameters. J Infect Dis 1994; 169:420-4.
25. Kalinkovich A, Engelmann H, Harpaz N et al. Elevated serum levels of soluble tumor necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Immunol 1992; 89:351-5.
26. Breen EC, Rezal AR, Nakajima K et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990; 144:480-4.
27. Honda M, Yamamoto S, Cheng M et al. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol 1992; 148:2175-80.
28. Sadeghi HM, Weiss L, Haeffner-Cavaillon N. Increased production of IL-1Ra and IL-8 is associated with CD4/CD8 imbalance ratio in HIV infected individuals. XI. International Conference on AIDS. Vancouver, 1496: Abstract We.A. 3104.
29. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41:1-19.
30. van Deuren M. Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin-1 beta and its receptor antagonist during serious infections. Eur J Clin Microbiol Infect Dis 1994; 13:12-16.
31. Poutsiaka DD, Clark BD, Vannier E et al. Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. Blood 1991; 78:1275-81.
32. Granowitz EV, Santos AA, Poutsiaka DD et al. Production of interleukin-1 receptor antagonist during experimental endotoxaemia. Lancet 1991; 338:1423-4.
33. Herbein G, Keshav S, Collin M et al. HIV-1 induces tumour necrosis factor and IL-1 gene expression in primary human macrophages independent of productive infection. Clin Exp Immunol 1994; 95:442-9.
34. Gershenwald JE, Fong YM, Fahey TJ et al. Interleukin-1 receptor blockade attenuates the host inflammalory response. Proc Natl Acad Sci USA 1990; 87:4966-70.
35. Berman MA, Zaldivar F Jr, Imfeld KL et al. HIV-1 infection of macrophages promotes long-term survival and sustained release of interleukins-1 alpha and 6. AIDS Res Hum Retrovid 1994; 10:529-39.
36. Burger D, Chicheportiche R, Giri J et al. The inhibitory effect of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 receptor and hindered by type I interleukin-1 receptor. J Clin Invest 1995; 96:38-41.
37. Kurrie R, Lauffer L, Röder J et al. Regulation of IL-1 activity by soluble IL-1 receptors. Behring Inst Mitt 1995; 96:45-57.